MX2018009937A - Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns). - Google Patents

Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns).

Info

Publication number
MX2018009937A
MX2018009937A MX2018009937A MX2018009937A MX2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A
Authority
MX
Mexico
Prior art keywords
methods
arylsulfatase
compositions
cns delivery
cns
Prior art date
Application number
MX2018009937A
Other languages
English (en)
Spanish (es)
Inventor
Wasilewski Margaret
Wijatyk Anna
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2018009937A publication Critical patent/MX2018009937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2018009937A 2016-02-17 2017-02-17 Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns). MX2018009937A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296563P 2016-02-17 2016-02-17
US201762453864P 2017-02-02 2017-02-02
PCT/US2017/018440 WO2017143233A1 (en) 2016-02-17 2017-02-17 Methods and compositions for cns delivery of arylsulfatase a

Publications (1)

Publication Number Publication Date
MX2018009937A true MX2018009937A (es) 2018-11-29

Family

ID=58192404

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009937A MX2018009937A (es) 2016-02-17 2017-02-17 Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns).
MX2024004034A MX2024004034A (es) 2016-02-17 2018-08-16 Composiciones de arilsulfatasa y usos farmaceuticos de las mismas en el sistema nervioso central (cns).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024004034A MX2024004034A (es) 2016-02-17 2018-08-16 Composiciones de arilsulfatasa y usos farmaceuticos de las mismas en el sistema nervioso central (cns).

Country Status (10)

Country Link
US (3) US11020461B2 (https=)
EP (1) EP3416678A1 (https=)
JP (4) JP2019509270A (https=)
CN (2) CN108883162A (https=)
AU (1) AU2017220100B2 (https=)
BR (1) BR112018016874A2 (https=)
CA (1) CA3014909A1 (https=)
MA (1) MA44237A (https=)
MX (2) MX2018009937A (https=)
WO (1) WO2017143233A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126376A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
BR112021021908A2 (pt) * 2019-05-03 2022-02-01 Univ Pennsylvania Composições úteis no tratamento da leucodistrofia metacromática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
NZ605874A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
SMT201600385T1 (it) * 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
NZ605873A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
CN103179980B (zh) * 2010-06-25 2016-09-28 夏尔人类遗传性治疗公司 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物

Also Published As

Publication number Publication date
EP3416678A1 (en) 2018-12-26
WO2017143233A1 (en) 2017-08-24
US20210315981A1 (en) 2021-10-14
AU2017220100B2 (en) 2024-04-04
CN108883162A (zh) 2018-11-23
JP2023159405A (ja) 2023-10-31
MX2024004034A (es) 2024-04-24
AU2017220100A1 (en) 2018-08-30
CN117224659A (zh) 2023-12-15
US20250099555A1 (en) 2025-03-27
US11020461B2 (en) 2021-06-01
JP2024102370A (ja) 2024-07-30
CA3014909A1 (en) 2017-08-24
BR112018016874A2 (pt) 2019-02-05
JP2021169528A (ja) 2021-10-28
MA44237A (fr) 2021-06-02
JP2019509270A (ja) 2019-04-04
US20200179492A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12020551427A1 (en) Epinephrine spray formulations
MX2021015427A (es) Vesiculas extracelulares microbianas procesadas.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12015500879A1 (en) Compositions and methods for treating proteinopathies
IL287715A (en) Useful preparations in the treatment of metachromatic leukodystrophy
MY190034A (en) Method of treating cancer associated with a ras mutation
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MX2018007227A (es) Tratamiento de colestasis intrahepatica y enfermedades hepaticas relacionadas.
NZ758331A (en) B cells for in vivo delivery of therapeutic agents and dosages thereof
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
DK2714888T3 (da) Rekombinant gær
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018009937A (es) Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns).